Company intelligence / Profile preview
Carcell Biopharma
Singapore, Singaporecarcell.com ↗
- Ownership
- Private
- Employees
- ~10
- Development stage
- Preclinical
01
Overview
Carcell Biopharma has established two lead technology platforms—engineered red blood cells for immunomodulation and a proprietary lipid nanoparticle system for nonviral gene delivery. The company’s first disclosed clinical program, CARC‑101C targeting Type I Diabetes, entered Phase I trials in August 2024. Other programs are at preclinical or IND-enabling stages. The company aims to address cancer, autoimmune conditions, rare diseases, and metabolic disorders with next-generation cell/gene therapies.
- Therapeutic areas
- OncologyEndocrinologyRare DiseasesImmunologyGastroenterology
- Modalities
- Engineered red blood cells for immunomodulationNon-viral gene delivery using lipid nanoparticles (LNPs)siRNA therapeutics
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Nanjing Drum Tower Hospital (clinical trial collaboration on CARC‑101C)
Beyond the preview
Go deeper on Carcell Biopharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Carcell Biopharma.